Loading...
XSTO
LIDDS
Market cap279kUSD
Apr 11, Last price  
0.03SEK
1D
-15.50%
1Q
-77.47%
Jan 2017
-99.45%
IPO
-99.66%
Name

Lidds AB

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.38%
Rev. gr., 5y
12.92%
Revenues
32k
0012,8797,6470001,028,5037,754,7080345,0003,554,0001,888,000032,000
Net income
-4m
L-89.28%
-1,875,302-3,482,198-3,712,308-3,889,997-7,063,673-7,815,219-6,634,079-6,669,276-3,747,681-23,833,063-32,342,000-37,270,000-37,103,000-40,206,000-4,311,000
CFO
-5m
L-79.28%
0-5,267,562-6,842,157-7,329,297-2,092,730-10,714,479-1,446,231-17,091,073-27,420,000-42,641,000-35,592,000-26,219,000-5,433,000
Earnings
May 28, 2025

Profile

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
URL
https://liddspharma.com/
IPO date
Jul 31, 2014
Employees
6
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
32
 
1,888
-46.88%
Cost of revenue
3,437
12,922
61,217
Unusual Expense (Income)
NOPBT
(3,405)
(12,922)
(59,329)
NOPBT Margin
Operating Taxes
12
243
Tax Rate
NOPAT
(3,417)
(12,922)
(59,572)
Net income
(4,311)
-89.28%
(40,206)
8.36%
(37,103)
-0.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
42,239
3,697
BB yield
-616.34%
-5.89%
Debt
Debt current
3,994
Long-term debt
Deferred revenue
Other long-term liabilities
636
5,578
Net debt
(5,507)
(13,512)
(1,264)
Cash flow
Cash from operating activities
(5,433)
(26,219)
(35,592)
CAPEX
(94)
(282)
(811)
Cash from investing activities
(94)
(282)
(810)
Cash from financing activities
(280)
34,755
7,657
FCF
(3,412)
(11,897)
(59,288)
Balance
Cash
5,507
13,512
5,258
Long term investments
Excess cash
5,505
13,512
5,164
Stockholders' equity
2,550
(352,539)
(314,109)
Invested Capital
4,265
366,438
333,189
ROIC
ROCE
EV
Common stock shares outstanding
121,794
63,456
37,007
Price
0.10
-6.02%
0.11
-93.63%
1.70
-82.24%
Market cap
12,362
80.38%
6,853
-89.08%
62,764
-80.92%
EV
6,855
(6,659)
61,500
EBITDA
(3,792)
(12,447)
(58,845)
EV/EBITDA
0.53
Interest
61
262
Interest/NOPBT